t
Hemogenyx Pharmaceuticals plc provided an update on the admission of new ordinary shares, following an announcement on 18 December 2025. The Financial Conduct Authority (FCA) notified the Company that the admission hearing is scheduled for 5 January 2026. Admission is expected to occur on or around 8.00 a.m. on 6 January 2026.
| Date | 22 Dec 2025 |
| Time | 08:00:01 |
| Category | Corporate updates |
| ID | 3721M |
22 December 2025
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Update on Admission of Shares
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, provides an update to the admission of new ordinary shares as announced on 18 December 2025.
The FCA has notified the Company that the admission hearing has been scheduled for the earliest available date being 5 January 2026, with admission expected to occur on or around 8.00 a.m. on 6 January 2026.
All other details outlined in the Company's announcement of 18 December 2025 remain unchanged.
Enquiries:
|
Hemogenyx Pharmaceuticals plc |
|
|
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder |
|
|
Peter Redmond, Director |
|
|
SP Angel Corporate Finance LLP |
Tel: +44 (0)20 3470 0470 |
|
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
|
AlbR Capital Limited |
Tel: +44 (0)20 7469 0930 |
|
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.